Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3413]

Novel JAK inhibitor pacritinib proving effective for easing symptoms of...

Dr Ruben Mesa - Mayo Clinic Cancer Center, Scottsdale, USA

Novel JAK inhibitor pacritinib proving effective for easing symptoms of myelofibrosis ( Dr Ruben Mesa - Mayo Clinic Cancer Center, Scottsdale, USA )

Novel targeted drug palbociclib slows progression of hormone receptor-positive...

Dr Nicholas Turner - The Institute of Cancer Research, London, UK

Novel targeted drug palbociclib slows progression of hormone receptor-positive breast cancer ( Dr Nicholas Turner - The Institute of Cancer Research, London, UK )

Anastrazole offers higher breast cancer-free survival rates than tamoxifen...

Prof Richard Margolese - The Jewish General Hospital, McGill University...

Anastrazole offers higher breast cancer-free survival rates than tamoxifen following DCIS ( Prof Richard Margolese - The Jewish General Hospital, McGill University, Montreal, Canada )

Eribulin extends overall survival for patients with advanced liposarcoma and...

Dr Patrick Schöffski - University Hospitals Leuven, Leuven, Belgium

Eribulin extends overall survival for patients with advanced liposarcoma and leiomyosarcoma ( Dr Patrick Schöffski - University Hospitals Leuven, Leuven, Belgium )

First effective adjuvant chemotherapy for high-risk, localised prostate cancer

Prof Howard Sandler - Cedars Sinai Medical Center, Los Angeles, USA.

First effective adjuvant chemotherapy for high-risk, localised prostate cancer ( Prof Howard Sandler - Cedars Sinai Medical Center, Los Angeles, USA. )

Novel JAK inhibitor pacritinib proves effective for easing symptoms of...

Dr Ruben Mesa - Mayo Clinic Cancer Center, Scottsdale, USA

Novel JAK inhibitor pacritinib proves effective for easing symptoms of myelofibrosis ( Dr Ruben Mesa - Mayo Clinic Cancer Center, Scottsdale, USA )

New ibrutinib combination regimen shows substantial benefits in relapsed...

Prof Asher Chanan-Khan - Mayo Clinic, Jacksonville, USA

New ibrutinib combination regimen shows substantial benefits in relapsed chronic lymphocytic leukaemia ( Prof Asher Chanan-Khan - Mayo Clinic, Jacksonville, USA )

First-in-class targeted drug daratumumab shows promise in heavily treatment...

Dr Saad Zafar Usmani - Levine Cancer Institute, Charlotte, USA

First-in-class targeted drug daratumumab shows promise in heavily treatment-resistant multiple myeloma ( Dr Saad Zafar Usmani - Levine Cancer Institute, Charlotte, USA )

Nivolumab shows highly promising activity in advanced liver cancer in early...

Dr Anthony El-Khoueiry - University of Southern California Norris Comprehensive...

Nivolumab shows highly promising activity in advanced liver cancer in early-stage trial ( Dr Anthony El-Khoueiry - University of Southern California Norris Comprehensive Cancer Center, Los Angeles, USA )

Prostate cancer and pharmacokinetics: Expert discussion

Prof Axel S. Merseburger and Prof Romano Danesi

Prostate cancer and pharmacokinetics: Expert discussion ( Prof Axel S. Merseburger and Prof Romano Danesi )

Latest developments in prostate cancer

Prof Peter Mulders, Prof Axel S. Merseburger, Prof Pablo Maroto, Prof Peter...

Latest developments in prostate cancer ( Prof Peter Mulders, Prof Axel S. Merseburger, Prof Pablo Maroto, Prof Peter Iversen )

Developments of tumour control probability (TCP) models for prostate cancer...

Dr Oscar Casaresa - Aarhus University, Aarhus, Denmark

Developments of tumour control probability (TCP) models for prostate cancer patients ( Dr Oscar Casaresa - Aarhus University, Aarhus, Denmark )

More from ecancer